Literature DB >> 22184120

Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1).

Yu-Chen Chang1, Chu-Hen Wu, Tzu-Chen Yen, Pin Ouyang.   

Abstract

Centrosomal protein 55 (Cep55), which is localized to the centrosome in interphase cells and recruited to the midbody during cytokinesis, is a regulator required for the completion of cell abscission. Up-regulation of Cep55 and inactivation of p53 occur in the majority of human cancers, raising the possibility of a link between these two genes. In this study we evaluated the role of p53 in Cep55 regulation. We demonstrated that Cep55 expression levels are well correlated with cancer cell growth rate and that p53 is able to negatively regulate Cep55 protein and promoter activity. Down-regulation of expression of Cep55 was accompanied by repression of polo-like kinase 1 (Plk1) levels due to p53 induction. Overexpression of Plk1 and knockdown of p53 expression both enhanced the post-translational protein stability of Cep55. BI 2356, a selective Plk1 inhibitor, however, prevented Cep55 accumulation in p53 knockdown cells while persistently keeping Plk1 levels elevated. Our results, therefore, indicate the existence of a p53-Plk1-Cep55 axis in which p53 negatively regulates expression of Cep55, through Plk1 which, in turn, is a positive regulator of Cep55 protein stability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22184120      PMCID: PMC3281710          DOI: 10.1074/jbc.M111.289108

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

Review 1.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

2.  Cep55 stabilization is required for normal execution of cytokinesis.

Authors:  Armando van der Horst; Jacinta Simmons; Kum Kum Khanna
Journal:  Cell Cycle       Date:  2009-11-10       Impact factor: 4.534

Review 3.  Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.

Authors:  Puneet Chopra; Gautam Sethi; Sunanda G Dastidar; Abhijit Ray
Journal:  Expert Opin Investig Drugs       Date:  2010-01       Impact factor: 6.206

4.  Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma.

Authors:  Satoko Inoda; Yoshihiko Hirohashi; Toshihiko Torigoe; Munehide Nakatsugawa; Kenji Kiriyama; Emiri Nakazawa; Kenji Harada; Hideo Takasu; Yasuaki Tamura; Kenjiro Kamiguchi; Hiroko Asanuma; Tetsuhiro Tsuruma; Takeshi Terui; Kunihiko Ishitani; Tosei Ohmura; Qiang Wang; Mark I Greene; Tadashi Hasegawa; Koichi Hirata; Noriyuki Sato
Journal:  J Immunother       Date:  2009-06       Impact factor: 4.456

Review 5.  BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1).

Authors:  R Wäsch; J Hasskarl; D Schnerch; M Lübbert
Journal:  Recent Results Cancer Res       Date:  2010

6.  A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.

Authors:  Surojit Sur; Raymond Pagliarini; Fred Bunz; Carlo Rago; Luis A Diaz; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

Review 7.  Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.

Authors:  Patrick Schöffski
Journal:  Oncologist       Date:  2009-05-27

8.  p53 negatively regulates expression of FoxM1.

Authors:  Bulbul Pandit; Marianna Halasi; Andrei L Gartel
Journal:  Cell Cycle       Date:  2009-10-25       Impact factor: 4.534

9.  Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity.

Authors:  C-H Chen; C-Y Chien; C-C Huang; C-F Hwang; H-C Chuang; F-M Fang; H-Y Huang; C-M Chen; H-L Liu; C-Y F Huang
Journal:  Oncogene       Date:  2009-06-15       Impact factor: 9.867

10.  FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation.

Authors:  Emilios Gemenetzidis; Amrita Bose; Adeel M Riaz; Tracy Chaplin; Bryan D Young; Muhammad Ali; David Sugden; Johanna K Thurlow; Sok-Ching Cheong; Soo-Hwang Teo; Hong Wan; Ahmad Waseem; Eric K Parkinson; Farida Fortune; Muy-Teck Teh
Journal:  PLoS One       Date:  2009-03-16       Impact factor: 3.240

View more
  11 in total

1.  MicroRNA-144-3p inhibits cell proliferation and induces cell apoptosis in prostate cancer by targeting CEP55.

Authors:  Hao Zheng; Zhenyu Guo; Xiaoqing Zheng; Weijie Cheng; Xing Huang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  High levels of centrosomal protein 55 expression is associated with poor clinical prognosis in patients with cervical cancer.

Authors:  Jingyi Qi; Gelin Liu; Fang Wang
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

3.  MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55.

Authors:  Yuanqin Yin; Jingjing Cai; Fandong Meng; Chengguang Sui; Youhong Jiang
Journal:  Cancer Biol Ther       Date:  2018-03-26       Impact factor: 4.742

Review 4.  Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis.

Authors:  J Jeffery; D Sinha; S Srihari; M Kalimutho; K K Khanna
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

5.  A truncating mutation in CEP55 is the likely cause of MARCH, a novel syndrome affecting neuronal mitosis.

Authors:  Patrick Frosk; Heleen H Arts; Julien Philippe; Carter S Gunn; Emma L Brown; Bernard Chodirker; Louise Simard; Jacek Majewski; Somayyeh Fahiminiya; Chad Russell; Yangfan P Liu; Robert Hegele; Nicholas Katsanis; Conrad Goerz; Marc R Del Bigio; Erica E Davis
Journal:  J Med Genet       Date:  2017-03-06       Impact factor: 6.318

6.  Identification of a p53-repressed gene module in breast cancer cells.

Authors:  Takafumi Miyamoto; Chizu Tanikawa; Varalee Yodsurang; Yao-Zhong Zhang; Seiya Imoto; Rui Yamaguchi; Satoru Miyano; Hidewaki Nakagawa; Koichi Matsuda
Journal:  Oncotarget       Date:  2017-07-26

7.  PART1 and hsa-miR-429-Mediated SHCBP1 Expression Is an Independent Predictor of Poor Prognosis in Glioma Patients.

Authors:  Chengmin Xuan; Mingwei Jin; Lei Wang; Shengbai Xue; Qi An; Qingzeng Sun; Lei Wang; Yong Gao
Journal:  Biomed Res Int       Date:  2020-04-13       Impact factor: 3.411

Review 8.  Centrosome-phagy: implications for human diseases.

Authors:  Qi Wu; Xin Yu; Le Liu; Shengrong Sun; Si Sun
Journal:  Cell Biosci       Date:  2021-03-04       Impact factor: 7.133

9.  Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness.

Authors:  Tao Peng; Wei Zhou; Feng Guo; He-Shui Wu; Chun-You Wang; Li Wang; Zhi-Yong Yang
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

10.  Cep55 overexpression promotes genomic instability and tumorigenesis in mice.

Authors:  Debottam Sinha; Purba Nag; Devathri Nanayakkara; Pascal H G Duijf; Andrew Burgess; Prahlad Raninga; Veronique A J Smits; Amanda L Bain; Goutham Subramanian; Meaghan Wall; John W Finnie; Murugan Kalimutho; Kum Kum Khanna
Journal:  Commun Biol       Date:  2020-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.